The main stock market index in the United States (US500) decreased 176 points or 2.99% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from United States. United States Stock Market Index - values, historical data, forecasts and news - updated on March of 2025.

Throughout the 1920s, prices on the U.S. stock exchange rose exponentially, however, by the end of the decade, uncontrolled growth and a stock market propped up by speculation and borrowed money proved unsustainable, resulting in the Wall Street Crash of October 1929. This set a chain of events in motion that led to economic collapse - banks demanded repayment of debts, the property market crashed, and people stopped spending as unemployment rose. Within a year the country was in the midst of an economic depression, and the economy continued on a downward trend until late-1932.

It was during this time where Franklin D. Roosevelt (FDR) was elected president, and he assumed office in March 1933 - through a series of economic reforms and New Deal policies, the economy began to recover. Stock prices fluctuated at more sustainable levels over the next decades, and developments were in line with overall economic development, rather than the uncontrolled growth seen in the 1920s. Overall, it took over 25 years for the Dow Jones value to reach its pre-Crash peak.

The main stock market index in the United Kingdom (GB100) increased 479 points or 5.86% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from United Kingdom. United Kingdom Stock Market Index (GB100) - values, historical data, forecasts and news - updated on March of 2025.

While the global coronavirus (COVID-19) pandemic caused all major stock market indices to fall sharply in March 2020, both the extent of the decline at this time, and the shape of the subsequent recovery, have varied greatly. For example, on March 15, 2020, major European markets and traditional stocks in the United States had shed around 40 percent of their value compared to January 5, 2020. However, Asian markets and the NASDAQ Composite Index only shed around 20 to 25 percent of their value. A similar story can be seen with the post-coronavirus recovery. As of November 14, 2021 the NASDAQ composite index value was around 65 percent higher than in January 2020, while most other markets were only between 20 and 40 percent higher.

Why did the NASDAQ recover the quickest?

Based in New York City, the NASDAQ is famously considered a proxy for the technology industry as many of the world’s largest technology industries choose to list there. And it just so happens that technology was the sector to perform the best during the coronavirus pandemic. Accordingly, many of the largest companies who benefitted the most from the pandemic such as Amazon, PayPal and Netflix, are listed on the NADSAQ, helping it to recover the fastest of the major stock exchanges worldwide.

Which markets suffered the most?

The energy sector was the worst hit by the global COVID-19 pandemic. In particular, oil companies share prices suffered large declines over 2020 as demand for oil plummeted while workers found themselves no longer needing to commute, and the tourism industry ground to a halt. In addition, overall share prices in two major stock exchanges – the London Stock Exchange (as represented by the FTSE 100 index) and Hong Kong (as represented by the Hang Seng index) – have notably recovered slower than other major exchanges. However, in both these, the underlying issue behind the slower recovery likely has more to do with political events unrelated to the coronavirus than it does with the pandemic – namely Brexit and general political unrest, respectively.

The main stock market index in Hong Kong (HK50) increased 3587 points or 17.88% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from Hong Kong. Hong Kong Stock Market Index (HK50) - values, historical data, forecasts and news - updated on March of 2025.

Over the course of their first terms in office, no U.S. president in the past 100 years saw as much of a decline in stock prices as Herbert Hoover, and none saw as much of an increase as Franklin D. Roosevelt (FDR) - these were the two presidents in office during the Great Depression. While Hoover is not generally considered to have caused the Wall Street Crash in 1929, less than a year into his term in office, he is viewed as having contributed to its fall, and exacerbating the economic collapse that followed. In contrast, Roosevelt is viewed as overseeing the economic recovery and restoring faith in the stock market played an important role in this.

By the end of Hoover's time in office, stock prices were 82 percent lower than when he entered the White House, whereas prices had risen by 237 percent by the end of Roosevelt's first term. While this is the largest price gain of any president within just one term, it is important to note that stock prices were valued at 317 on the Dow Jones index when Hoover took office, but just 51 when FDR took office four years later - stock prices had peaked in August 1929 at 380 on the Dow Jones index, but the highest they ever reached under FDR was 187, and it was not until late 1954 that they reached pre-Crash levels once more.

The main stock market index In the Euro Area (EU50) increased 521 points or 10.65% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from Euro Area. Euro Area Stock Market Index (EU50) - values, historical data, forecasts and news - updated on March of 2025.

The disaster recovery-as-a-service market is estimated to be valued at US$ 23.4 billion in 2024. The snail mucin skincare market is predicted to rise at a CAGR of 24.8% from 2024 to 2034. The global disaster recovery-as-a-service market is anticipated to reach US$ 214.3 billion by 2034.

Attributes	Key Insights
Estimated Market Size in 2024	US$ 23.4 billion
Projected Market Value in 2034	US$ 214.3 billion
Value-based CAGR from 2024 to 2034	24.8%

2019 to 2023 Historical Analysis vs. 2024 to 2034 Market Forecast Projections

Historical CAGR (2019 to 2023)	22.6%
Forecasted CAGR (2024 to 2034)	24.8%

Country-wise Analysis

Countries	Forecast CAGRs from 2024 to 2034
The United States	21.60%
Germany	20.20%
Japan	19.50%
China	25.30%
Australia	28.30%

Category-wise Insights

Category	Market Share
Data Protection Service	28.2%
Telecommunication Service Provider	36.2%

Report Scope

Attributes	Details
Estimated Market Size in 2024	US$ 23.4 billion
Projected Market Valuation in 2034	US$ 214.3 billion
Value-based CAGR 2024 to 2034	24.80%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	Value in US$ million
Key Regions Covered	North America Latin America Western Europe Eastern Europe South Asia and Pacific East Asia The Middle East and Africa
Key Market Segments Covered	Service Type Deployment Organization Size Industry Vertical Region
Key Countries Profiled	The United States Canada Brazil Mexico Germany The United Kingdom France Spain Italy Russia Poland Czech Republic Romania India Bangladesh Australia New Zealand China Japan South Korea GCC countries South Africa Israel
Key Companies Profiled	Amazon Web Services Axcient Citrix IBM Microsoft NTT Communication Sunguard Cable & Wireless Communication TierPoint, LLC Recovery Point Systems Cisco Systems

The Long Depression was, by a large margin, the longest-lasting recession in U.S. history. It began in the U.S. with the Panic of 1873, and lasted for over five years. This depression was the largest in a series of recessions at the turn of the 20th century, which proved to be a period of overall stagnation as the U.S. financial markets failed to keep pace with industrialization and changes in monetary policy. Great Depression The Great Depression, however, is widely considered to have been the most severe recession in U.S. history. Following the Wall Street Crash in 1929, the country's economy collapsed, wages fell and a quarter of the workforce was unemployed. It would take almost four years for recovery to begin. Additionally, U.S. expansion and integration in international markets allowed the depression to become a global event, which became a major catalyst in the build up to the Second World War. Decreasing severity When comparing recessions before and after the Great Depression, they have generally become shorter and less frequent over time. Only three recessions in the latter period have lasted more than one year. Additionally, while there were 12 recessions between 1880 and 1920, there were only six recessions between 1980 and 2020. The most severe recession in recent years was the financial crisis of 2007 (known as the Great Recession), where irresponsible lending policies and lack of government regulation allowed for a property bubble to develop and become detached from the economy over time, this eventually became untenable and the bubble burst. Although the causes of both the Great Depression and Great Recession were similar in many aspects, economists have been able to use historical evidence to try and predict, prevent, or limit the impact of future recessions.

The main stock market index in Russia (MOEX) increased 264 points or 9.16% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from Russia. Russia Stock Market Index MOEX CFD - values, historical data, forecasts and news - updated on March of 2025.

As of August 2020, the S&P 500 index had lost 34 percent of its value due to the COVID-19 pandemic. However, the Great Crash, which began with Black Tuesday, remains the most significant loss in value in its history. That market crash lasted for 300 months and wiped 86 percent off the index value.

The main stock market index in France (FR40) increased 650 points or 8.81% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from France. France Stock Market Index (FR40) - values, historical data, forecasts and news - updated on March of 2025.

The main stock market index in Brazil (IBOVESPA) increased 12164 or 10.11% since the beginning of 2025, according to trading on a contract for difference (CFD) that tracks this benchmark index from Brazil. Brazil Stock Market (BOVESPA) - values, historical data, forecasts and news - updated on March of 2025.

Between March 4 and March 11, 2020, the S&P 500 index declined by twelve percent, descending into a bear market. On March 12, 2020, the S&P 500 plunged 9.5 percent, its steepest one-day fall since 1987. The index began to recover at the start of April and reached a peak in December 2021. As of December 29, 2024, the value of the S&P 500 stood at 5,942.47 points. Coronavirus sparks stock market chaos Stock markets plunged in the wake of the COVID-19 pandemic, with investors fearing its spread would destroy economic growth. Buoyed by figures that suggested cases were leveling off in China, investors were initially optimistic about the virus being contained. However, confidence in the market started to subside as the number of cases increased worldwide. Investors were deterred from buying stocks, and this was reflected in the markets – the values of the Dow Jones Industrial Average and the Nasdaq Composite also dived during the height of the crisis. What is a bear market? A bear market occurs when the value of a stock market suffers a prolonged decline of more than 20 percent over a period of at least two months. The COVID-19 pandemic caused severe concern and sent stock markets on a steep downward spiral. The S&P 500 achieved a record closing high of 3,386 on February 19, 2020. However, just over three weeks later, the market closed on 2,480, which represented a decline of around 26 percent in only 16 sessions.

Market Overview:

The 7 major gastroesophageal junction adenocarcinoma markets are expected to exhibit a CAGR of 13.82% during 2024-2034.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2034
Historical Years	2018-2023
Market Growth Rate 2024-2034	13.82%

The gastroesophageal junction adenocarcinoma market has been comprehensively analyzed in IMARC's new report titled "Gastroesophageal Junction Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gastroesophageal junction adenocarcinoma is a type of cancer arising from the glandular cells that line the inner surface of the esophagus. The symptoms of this ailment can vary depending on the stage and location of the tumor. Some common indications associated with the illness include difficulty swallowing, unintended weight loss, chest pain or discomfort, indigestion, worsening heartburn, black or tarry stools, vomiting, nausea, fatigue, pale skin, coughing, hoarseness, shortness of breath, etc. These symptoms may gradually develop or become more pronounced as the tumor grows and affects the function of the digestive system. The diagnosis of gastroesophageal junction adenocarcinoma typically involves a combination of the patient's clinical features, medical history, and physical examination. Various imaging tests, such as upper endoscopic ultrasound, X-ray, positron emission tomography (PET) scan, etc., are also utilized to evaluate the extent and spread of cancer. The healthcare provider may further conduct molecular testing of tumor tissue to identify specific genetic mutations or alterations associated with the condition. In some cases, an imaging-guided biopsy is recommended to determine the presence of cancer and confirm its type and grade.

https://www.imarcgroup.com/CKEditor/e90b8e2f-652b-49b9-a009-feffa4cd146cgastroesophageal-junction-adenocarcinoma-market.webp" style="height:450px; width:800px" />

The increasing cases of chronic acid reflux, which causes long-lasting inflammation and damage to the lining of the esophagus, are primarily driving the gastroesophageal junction adenocarcinoma market. In addition to this, the rising prevalence of mutations in tumor suppressor genes that help to regulate cell division and prevent the formation of cancerous cells is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, such as trastuzumab, ramucirumab, pembrolizumab, etc., to treat the ailment is further bolstering the market growth. These agents inhibit specific proteins or signaling pathways involved in disease progression, thereby improving the quality of life for patients. Apart from this, the inflating application of endoscopic mucosal resection procedures, since they can remove abnormal or cancerous tissue in the gastrointestinal tract while preserving the surrounding healthy cells, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryotherapy owing to its various advantages, like smaller incisions, reduced risk of complications, faster recovery times, etc., is expected to drive the gastroesophageal junction adenocarcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the gastroesophageal junction adenocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gastroesophageal junction adenocarcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastroesophageal junction adenocarcinoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gastroesophageal junction adenocarcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gastroesophageal junction adenocarcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current gastroesophageal junction adenocarcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Drugs	Company Name
Enhertu (Trastuzumab deruxtecan)	AstraZeneca/Daiichi Sankyo
Cyramza (Ramucirumab)	Eli Lilly and Company
Taxotere (Docetaxel)	Sanofi Aventis
Lonsurf (Tipiracil/trifluridine)	Taiho Pharmaceutical
Herceptin (Trastuzumab)	Genentech
Evorpacept (ALX148)	ALX Oncology
Tucatinib	Seagen
Bemarituzumab	Amgen
DKN-01	Leap Therapeutics
TORL-2-307-MAB	TORL Biotherapeutics

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the gastroesophageal junction adenocarcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the gastroesophageal junction adenocarcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the gastroesophageal junction adenocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of gastroesophageal junction adenocarcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gastroesophageal junction adenocarcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gastroesophageal junction adenocarcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with gastroesophageal junction adenocarcinoma across the seven major markets?
• What is the size of the gastroesophageal junction adenocarcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of

After a thorough study of the healthcare domain, Future Market Insights speculates a positive yet moderate growth forecast for the biopsy device market from 2024 to 2034. Current projections indicate a valuation of US$ 2,274.1 million in 2024 for this market.

Attributes	Key Insights
Estimated Market Size in 2024	US$ 2,274.1 million
Projected Market Value in 2034	US$ 3,270.4 million
Value-based CAGR from 2024 to 2034	3.70%

Country-wise Analysis

Countries	Forecasted CAGR
Canada	2.60%
France	4.30%
Spain	4.10%
India	5.80%
Thailand	4.50%

Category-wise Insights

Category	Product Type - Needles
Market Share in 2024	36.6%
Market Segment Drivers	Due to the high reliability of needle biopsy, medical professionals prefer this market segment, and hence, it surges the demand for the subject segment. Biopsy treatment given under this segment is less invasive. Due to this, it provides comfort to patients. Hence, this surges the demand for the segment. The better recovery time adds points to the segment’s account, fueling its growth.

Category	Application - Medical Diagnosis
Market Share in 2024	61.3%
Market Segment Drivers	Increased prevalence of medical awareness surges patients to preventive check-ups. This fuels the progress of the market segment. The accuracy of medical diagnosis is more, which propels the trustworthiness of the segment. Hence, consumers prefer the segment more. Preserving and researching infected tissues with a rare disease can develop medical science. This advances the market segment.

Report Scope

Attributes	Details
Estimated Market Size in 2024	US$ 2274.1 million
Projected Market Valuation in 2034	US$ 3270.4 million
Value-based CAGR 2024 to 2034	3.70%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	Value in US$ million
Key Regions Covered	North America Latin America Western Europe Eastern Europe South Asia and Pacific East Asia The Middle East and Africa
Key Market Segments Covered	By Product Type By Application By End Use Region
Key Countries Profiled	The United States Canada Brazil Mexico Germany The United Kingdom France Spain Italy Poland Russia Czech Republic Romania India Bangladesh Australia New Zealand China Japan South Korea GCC Countries South Africa Israel
Key Companies Profiled	CR Bard Becton, Dickinson, and Company B. Braun Melsungen AG Hologic Inc. Cook Medical Devicor Medical Products Inc. Argon Medical Inc.

As of January 29, 2025, the FTSE index stood at 8,557.81 points - well above its average value of around 7,500 points in the past few years.On the 12th of March 2020, amid the escalating crisis surrounding the coronavirus and fears of a global recession, the FTSE 100 suffered the second largest one day crash in its history and the biggest since the 1987 market crash. On the 23rd of March, the FTSE index saw its lowest value this year to date at 4,993.89 but has since began a tentative recovery. With the continuation of the pandemic, the FTSE 100 index was making a tentative recovery between late March 2020 and early June 2020. Since then the FSTE 100 index had plateaued towards the end of July, before starting a tentative upward trend in November. FTSE 100 The Financial Times Stock Exchange 100 Index, otherwise known as the FTSE 100 Index is a share index of the 100 largest companies trading on the London Stock Exchange in terms of market capitalization. At the end of March 2024, the largest company trading on the LSE was Shell. The largest ever initial public offering (IPO) on the LSE was Glencore International plc. European stock exchanges While nearly every country in Europe has a stock exchange, only five are considered major, and have a market capital of over one trillion U.S dollars. European stock exchanges make up two of the top ten major stock markets in the world. Europe’s biggest stock exchange is the Euronext which combines seven markets based in Belgium, France, England, Ireland, the Netherlands, Norway, and Portugal.

The massage guns market is set to witness significant growth from 2025 to 2035, driven by increasing consumer awareness regarding muscle recovery, stress relief, and fitness-related therapies. The market is expected to grow from USD 1.5 billion in 2025 to USD 3.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.1% over the forecast period.

Metric	Value
Industry Size (2025E)	USD 1.5 billion
Industry Value (2035F)	USD 3.7 billion
CAGR (2025 to 2035)	8.1%

Top 5 Countries Driving the Massage Guns Market

Country	United States
Population (millions)	345.4
Estimated Per Capita Spending (USD)	15.20

Country	China
Population (millions)	1,419.3
Estimated Per Capita Spending (USD)	8.30

Country	Germany
Population (millions)	84.1
Estimated Per Capita Spending (USD)	12.40

Country	United Kingdom
Population (millions)	68.3
Estimated Per Capita Spending (USD)	11.10

Country	Japan
Population (millions)	123.3
Estimated Per Capita Spending (USD)	9.70

Massage Guns Market - Global Country-Wise Outlook

Country	CAGR (2025 to 2035)
United States	7.5%

Country	CAGR (2025 to 2035)
United Kingdom	7.2%

Country	CAGR (2025 to 2035)
Germany	7.4%

Country	CAGR (2025 to 2035)
India	8.1%

Country	CAGR (2025 to 2035)
China	8.5%

Competition Outlook

Company Name	Estimated Market Share (%)
Therabody	15-20%
Hyperice	10-15%
TimTam	5-10%
DMS	5-10%
Other Companies	50-65%

Market Overview:

The 7 major Fuchs dystrophy markets reached a value of US$ 148.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 292.9 Million by 2034, exhibiting a growth rate (CAGR) of 6.38% during 2024-2034.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2034
Historical Years	2018-2023
Market Size in 2023	US$ 148.3 Million
Market Forecast in 2034	US$ 292.9 Million
Market Growth Rate (2024-2034)	6.38%

The Fuchs dystrophy market has been comprehensively analyzed in IMARC's new report titled "Fuchs Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fuchs dystrophy is a progressive eye disease that damages the cornea, which is the transparent, dome-shaped surface that covers the front of the eye. It is a hereditary condition that affects women more frequently than men. The main symptom of the ailment is gradual loss of vision, which typically begins in the morning and improves throughout the day. As the condition progresses, patients may experience increased sensitivity to light, blurred vision, and difficulty seeing at night. In advanced cases, fluid may accumulate in the cornea, causing swelling and distortion of vision. Fuchs dystrophy can be diagnosed through a comprehensive eye exam performed by an ophthalmologist. During the exam, the doctor will evaluate the patient's vision and check for signs of corneal swelling or thickening. They also use a special microscope called a slit lamp to examine the cornea in detail and assess the health of the cells that line its surface. In addition to this, the doctor may perform specular microscopy, which uses a special camera to create a high-resolution image of the cornea's inner layer. This can help to detect changes in the cells that may indicate the presence of Fuchs dystrophy. In a few cases, genetic testing is also recommended to confirm the diagnosis.

https://www.imarcgroup.com/CKEditor/ee83cc7d-2e2c-4b1d-af24-a64009095104fuchs-dystrophy-market.webp" style="height:450px; width:800px" />

The increasing cases of genetic mutations that affect the production of proteins in the cornea, which further lead to progressive thinning and clouding of the cornea, are primarily driving the Fuchs dystrophy market. In addition to this, the inflating adoption of steroids and nonsteroidal anti-inflammatory drugs to reduce inflammation and swelling in the cornea, thereby improving vision and easing discomfort, is also bolstering the market growth. Moreover, the rising application of phototherapeutic keratectomy (PTK) to remove excess corneal tissue and smooth out the surface of the cornea is acting as another significant growth-inducing factor. Apart from this, the escalating demand for bandage contact lenses, since they protect the cornea from further damage by providing a smooth surface for the eyelid to glide over, is creating a positive outlook for the market. They also aid in alleviating swelling and improving vision by drawing excess fluid from the cornea. Additionally, the emerging popularity of Descemet membrane endothelial keratoplasty on account of its several associated benefits, such as reduced risk of rejection, lowered likelihood of astigmatism, minimal impact on the cornea, faster recovery time, etc., is expected to drive the Fuchs dystrophy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Fuchs dystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Fuchs dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Fuchs dystrophy market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Fuchs dystrophy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Fuchs dystrophy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Fuchs dystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Drugs	Company Name
Netarsudil	Alcon
Ripasudil	Kowa Pharmaceutical
STN1010904	ActualEyes/Santen Pharmaceutical
TTHX 1114	Trefoil Therapeutics

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Fuchs dystrophy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Fuchs dystrophy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Fuchs dystrophy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

<ul

The Dow Jones Industrial Average posted significant points losses due to the global impact of the coronavirus pandemic in 2020. With stocks falling sharply, the Dow recorded its worst single-day points drop ever, plunging 2,997 points – nearly 13 percent – on March 16, 2020.

Boeing stock hits turbulence The Dow Jones Industrial Average (DJIA) is a stock market index that tracks the share prices of the top 30 U.S. companies. Due to the outbreak of COVID-19, firms heavily dependent on travel and tourism had a particularly difficult start to the year. Due to lower production rates and the suspension of flights in the first quarter of 2020, Boeing’s revenue dropped to 16.9 billion U.S. dollars – this represented a year-on-year decline of 26 percent. However, in the second quarter of 2020, Boeing was one of the leading stocks in the DJIA index. Shares were boosted by the relaxing of travel restrictions and greater passenger confidence in flying.

Comparing market collapses Index points represent changes in the collective value of the 30 stocks in the DJIA, providing the general direction of the market. March 2020 was one of the most volatile months in the history of the stock index. Not only did the market record significant losses, but it also saw dramatic one-day points gains. Percentages can also be used to gain a deeper understanding of the true value gained or lost on the market. The largest single-day percentage loss in the history of the Dow remains ‘Black Monday’ in October 1987.